| Course | NR 568 Advanced Pharmacology for the Adult-Gerontology Primary Care Nurse Practitioner |
|---|---|
| Week | 8 |
| Paper type | Pharmacotherapy synthesis |
| Length | About 1,110 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Adult-Gerontology Primary Care NP (AGPCNP) |
| Updated | October 2026 |
Free sample paper for NR 568 Week 8
Pharmacotherapy Synthesis: One Regimen Defended End to End for a 79-Year-Old With Kidney Disease, Shown as It Arrived and as It Now Stands, With Every Survivor Given a Sentence
Student Name
College of Nursing, Chamberlain University
NR 568: Advanced Pharmacology for the Adult-Gerontology Primary Care Nurse Practitioner
Instructor Name
Month Day, Year
Pharmacotherapy Synthesis: One Regimen Defended End to End for a 79-Year-Old With Kidney Disease, Shown as It Arrived and as It Now Stands, With Every Survivor Given a Sentence
The Test Applied to Every Entry
Every entry in this patient's regimen faced one test: does it treat a current problem, at a dose the kidney and age allow, without stacking with another entry in a way that harms the patient, and can the household take it as prescribed? The answer for each entry is recorded below. Applying the same test to every entry is what makes this a synthesis rather than a set of separate decisions.
The Regimen Twice
Table 1
The Regimen as It Arrived and as It Now Stands
| As it arrived (September) | As it now stands (December) |
|---|---|
| Metformin 1,000 mg twice daily | Metformin, extended-release form, 1,000 mg at supper |
| Allopurinol 300 mg daily | Allopurinol 400 mg daily, urate pending |
| Lisinopril 40 mg daily | Lisinopril 40 mg daily |
| Chlorthalidone 12.5 mg, raised to 25 mg | Stopped (hyponatremia); amlodipine 2.5 mg daily |
| Citalopram 40 mg daily | Citalopram 20 mg daily |
| Atorvastatin 40 mg at bedtime | Atorvastatin 40 mg at bedtime |
| Trazodone 100 mg at bedtime | Tapering; 50 mg at bedtime |
| Doxazosin 4 mg at bedtime | Stopped |
| Tamsulosin 0.4 mg daily | Tamsulosin 0.4 mg, now half an hour after supper |
| Levothyroxine 100 mcg with breakfast | Levothyroxine 100 mcg on waking, before breakfast |
| Calcium carbonate with breakfast | Calcium carbonate with lunch |
| Diphenhydramine, meclizine, naproxen (over the counter) | Stopped; acetaminophen as needed |
| Colchicine 0.3 mg daily, six months |
Additions With Arithmetic
Amlodipine 2.5 mg daily replaced chlorthalidone after the sodium fell to 126. It needs no kidney adjustment, does not lower sodium, and adds to lisinopril on a different mechanism. Sitting pressure has settled at about 134/80.
Colchicine 0.3 mg daily, a reduced dose chosen for a creatinine clearance of about 33 mL/min (Cockcroft-Gault: age 79, 70 kg and a creatinine of 1.8 give roughly 33) and for the atorvastatin interaction, provides flare prophylaxis while allopurinol is raised (FitzGerald et al., 2020).
Allopurinol rose from 300 to 400 mg, above the old kidney-based ceiling but consistent with titration to a urate target in chronic kidney disease (FitzGerald et al., 2020); the urate result on 3 November was 7.0 mg/dL, so a further step to 500 mg is planned in January.
Removals With Schedules
Doxazosin was tapered from 4 mg to 2 mg to 1 mg over two weeks and stopped on 20 October. Standing systolic drop fell from 28 to 12 mm Hg.
Meclizine stopped on 3 November and diphenhydramine on 10 November, with a sleep plan.
Naproxen stopped at the first visit, replaced by acetaminophen up to 3 g daily.
Chlorthalidone stopped on 22 November after hyponatremia, recorded as an intolerance.
Trazodone is tapering, 100 mg to 50 mg on 24 November, with 25 mg planned for 8 December and a stop on 22 December if sleep holds.
Deprescribing was done one entry at a time, with the patient's goals guiding the order (Reeve et al., 2014).
Survivors With Sentences
Lisinopril 40 mg stays because it controls blood pressure and slows kidney disease progression in diabetes, and potassium remains normal.
Atorvastatin 40 mg stays because the patient has a coronary stent and secondary prevention benefits are strong; the household budget changes made it affordable to take every day.
Citalopram 20 mg stays because depression is in remission; the PHQ-9 was 3 at eight weeks after the reduction.
Metformin stays, at a kidney-appropriate total dose and a once-daily extended-release form, because the A1c is 6.6% and it rarely causes hypoglycemia (Rossing et al., 2022).
Tamsulosin stays because prostate symptoms are real, and as the single alpha blocker it is acceptable now that orthostatic readings have improved.
Levothyroxine stays at the same dose with corrected timing; a thyroid-stimulating hormone level is due in six weeks.
Calcium stays, moved to lunch, pending a discussion of bone density.
Where the Organ Sets the Ceiling
The kidney sets the ceiling for metformin (about one gram a day at this filtration level), colchicine (reduced dose) and any future antibiotic. It does not set the ceiling for allopurinol in the way older tables implied, and the synthesis records that distinction so that a future prescriber does not reduce allopurinol back to 200 mg on the basis of an outdated table.
What Would Reopen It
The regimen will be reopened by any of the following: an estimated glomerular filtration rate falling below 30 mL/min/1.73 m2 (metformin would stop and colchicine would be reconsidered); a sodium below 133; a fall; a PHQ-9 above 10; a urate still above 6 mg/dL on 500 mg of allopurinol; or a new prescription from another clinician that interacts with citalopram or atorvastatin.
The Patient's View
The patient reports no dizziness on standing for four weeks and is sleeping about six hours. The spouse now fills the pill box in 15 minutes. That outcome, more than any single change, is what the regimen as it stands was built to achieve.
How the Regimen Will Be Kept Current
A synthesis is only accurate on the day it is written. The practice will repeat a brown-bag review every six months, ask at every visit whether any other clinician has prescribed something, and send the current list to the urgent care clinic and the cardiologist. The pharmacist has the list and the reasons for each change, so that refills of stopped medicines are flagged rather than filled.
What Remains Uncertain
Some questions are open. The urate target is not yet reached. The trazodone taper may stall if sleep worsens. Kidney function may decline further. The synthesis records these as open items with dates for review, so that the next clinician inherits the reasoning as well as the list.
Who Holds the Regimen Now
The practice holds the regimen and its reasons, but the patient and spouse hold it day to day. They have a printed list with each medicine, its purpose in plain words, its time of day and the date of its next review. The cardiologist, urologist and rheumatologist have copies. Each specialist was asked to send any change back to the practice before the patient leaves their office, so that the regimen as it stands does not slowly drift back toward the regimen as it first arrived in September.
References
FitzGerald, J. D., Dalbeth, N., Mikuls, T., BrignardelloâPetersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., Levy, G., Libbey, C., Mount, D., Pillinger, M. H., Rosenthal, A., Singh, J. A., Sims, J. E., Smith, B. J., Wenger, N. S., . . . Neogi, T. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760. https://doi.org/10.1002/acr.24180
Reeve, E., Shakib, S., Hendrix, I., Roberts, M. S., & Wiese, M. D. (2014). Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. British Journal of Clinical Pharmacology, 78(4), 738-747. https://doi.org/10.1111/bcp.12386
Rossing, P., Caramori, M. L., Chan, J. C., Heerspink, H. J., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., Tandon, N., Tuttle, K. R., Wanner, C., Wilkens, K. G., Zoungas, S., & de Boer, I. H. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5), S1-S127. https://doi.org/10.1016/j.kint.2022.06.008
What the NR 568 Week 8 assignment asks for
The final synthesis usually asks you to defend a complete regimen for one patient, including what you added, what you removed and what you kept. Most prompts here call for the full regimen, the rationale for each entry, dosing against organ function, monitoring and future review. Apply one test to every entry and state it. Show the regimen as it arrived and as it now stands, side by side. Give each addition its calculation or threshold. Give each removal its schedule. Give each surviving entry a sentence explaining why it stays. Explain where organ function limits a dose. Finish with the events that would reopen the regimen and how it will be kept current.
Inside the NR 568 Week 8 example
The sample states its test: a current problem, a safe dose for this kidney and age, no harmful stacking and a schedule the household can keep. A table shows thirteen products in September beside the December regimen. Additions follow with numbers: amlodipine after the sodium event, reduced-dose colchicine with the clearance shown, and allopurinol raised with a urate result. Removals list their dates, from the doxazosin taper to the planned trazodone stop. Each survivor gets a sentence, from lisinopril's kidney protection to levothyroxine's corrected timing. A section separates drugs whose dose the kidney limits from allopurinol, whose old ceiling no longer applies. Reopening events, open questions and the patient's report close the paper.
Reading the NR 568 Week 8 grading rubric
Syntheses are commonly assessed on whether every entry was examined, whether additions carry their arithmetic, whether removals have schedules, whether survivors are explained and whether future review is planned. A paper that argues the changes and says nothing about what stayed loses the most, so every surviving entry here receives a reason. Showing the regimen twice makes the distance covered visible. Additions with clearance figures and thresholds let a reader check each dose. Removals with taper dates show how each change was made. Distinguishing drugs limited by the kidney from allopurinol shows current knowledge. Listing reopening events and open questions shows the regimen is managed rather than finished. Guideline and deprescribing citations support the decisions throughout.
NR 568 Week 8 help: mistakes that cost points
What sinks a synthesis fastest is a paper that discusses only the changes, leaving a reader unable to tell whether the unchanged entries were reviewed. Another common problem is an addition with no dose calculation, especially in kidney disease. Many papers list removals without schedules, so tapers and dates are lost. Some apply a ceiling the guidance no longer supports. Others end without saying what would trigger another review. State one test, show the regimen twice, give additions their arithmetic, removals their schedules and survivors their sentences, and list what would reopen it. A synthesis for your own patient can be written from the starting and current regimens you share.
Get a NR 568 Week 8 example written to your instructions
Send the Week 8 case, the rubric and whatever length your section set, and a complete example synthesis is written to them and returned inside 24 to 48 hours, the first one free. It arrives with the additions dosed, the removals scheduled and the surviving entries each given the sentence that keeps them there.
More NR 568 papers and AGPCNP samples
- NR 568 Week 1: Citalopram Dose Discussion Post
- NR 568 Week 2: Medication List Review
- NR 568 Week 3: Clarithromycin Interaction Analysis
- NR 568 Week 4: Allopurinol in CKD Case Analysis
- NR 568 Week 5: Deprescribing Plan
- NR 568 Week 6: Hyponatremia Adverse Effect Write-Up
- NR 568 Week 7: Polypharmacy Case Study
NR 568 Week 8 questions, answered
Does every unchanged entry really need its own sentence?
A short one, yes, and the section is usually quicker to write than people expect. Naming what an entry is still achieving, or the reason it is being left where it is for now, turns a silence into a decision. Where several are unchanged for the same reason they can be grouped, provided that reason is specific. What fails is a closing line saying the rest of the regimen was continued.
Should the paper use the same patient it has worked on all term?
Follow whatever your section published, since some carry one case forward and others supply a fresh one. Where the case is new, resist writing it as though the earlier weeks never happened. The counting, the arithmetic and the removal schedules are the method the course has spent eight weeks building, and a final paper abandoning them for a single prescribing decision reads as a step backwards.
Do sources belong against the removals as well as the additions?
They do, and this is where most final papers leave a gap. A stop is a therapeutic action, and the claim that an agent can be reduced across a set number of weeks, or halted with no stepping down at all, came from somewhere and can be checked. A withdrawal schedule with nothing behind it, in a paper whose background paragraphs carry three citations each, gets noticed.
Where can I find a free NR 568 Week 8 sample paper?
The end-to-end synthesis above, with the regimen shown as it arrived and as it now stands, is the full NR 568 Week 8 sample. A synthesis for your own patient can be prepared on request.
Why does every kept medicine get a sentence in NR 568 Week 8?
Because the synthesis must show that every entry passed the same test; a reason beside each survivor proves it was examined rather than skipped.